Protalix BioTherapeutics, Inc. (PLX)
-NYSE MKT | Prev Close: | 5.20 |
|---|
| Open: | N/A |
|---|
| Bid: | 5.20 x 1000 |
|---|
| Ask: | 5.26 x 1000 |
|---|
| 1y Target Est: | 6.00 |
|---|
| Beta: | 1.25 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 4.71 - 6.80 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 169,697 |
|---|
| Market Cap: | 479.36M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.11 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- PLX July Options Begin Tradingat TheStreet(Tue, 04:20 SGT)
- PROTALIX BIOTHERAPEUTICS, INC. FinancialsEDGAR Online Financials(Sat, 18 May)
- Protalix Bio gets vote of confidenceoptionMONSTER(Tue, 14 May)
- PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, 9 May)
- Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli ConferenceGlobeNewswire(Wed, 8 May)
- Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc., Interviews with The Wall Street Transcript: Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan DrugsWall Street Transcript(Wed, 1 May)
- J.C. Penney Lands a Loan, Protalix Rides on Approval, and 3 Other Hot Stocksat Wall St. Cheat Sheet(Mon, 29 Apr)
- UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher DiseaseGlobeNewswire(Mon, 29 Apr)
- PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Mon, 29 Apr)
- Update on Protalix Gaucher StudyZacks(Fri, 5 Apr)
Key Statistics
| Forward P/E (1 yr): | 520.00 |
|---|
| P/S (ttm): | 13.83 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.16 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | -1.33 |
|---|
Business Summary
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression sy...
View More 
0.30%